Company / SG&A Expense
Ventyx Biosciences, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$31.4M
FY2024
5-year range
$684.0K / $32.2M
FY2020-FY2024
Trend
-2.4%
vs FY2023
Sector context
#179 of 212
Health Care
What the data says
Ventyx Biosciences, Inc.'s sg&a expense of $31M is lower than 84% of companies in the Health Care sector (FY2024). Increased from $25M to $31M over the past 2 years.
Based on SEC 10-K filings.
$31M in FY2024 with a 3-year CAGR of +53.7%.
Increased from $25M to $31M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +53.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 212This company $31.4M Sector average $722.9M
▼
-95.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +53.7%, indicating consistent growth.
- In FY2024, sg&a expense decreased 2.4% year-over-year.
- Ranks #179 out of 212 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $31.4M | -2.4% |
| FY2023 | $32.2M | +26.9% |
| FY2022 | $25.4M | +193.1% |
| FY2021 | $8.7M | +1167.0% |
| FY2020 | $684.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026